Author: Prokunina-Olsson, Ludmila; Alphonse, Noémie; Dickenson, Ruth E.; Durbin, Joan E.; Glenn, Jeffrey S.; Hartmann, Rune; Kotenko, Sergei V.; Lazear, Helen M.; O’Brien, Thomas R.; Odendall, Charlotte; Onabajo, Olusegun O.; Piontkivska, Helen; Santer, Deanna M.; Reich, Nancy C.; Wack, Andreas; Zanoni, Ivan
Title: COVID-19 and emerging viral infections: The case for interferon lambda Cord-id: cz1emxxh Document date: 2020_4_14
ID: cz1emxxh
Snippet: With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-λ) realized that this class of IFNs could play an important role in this and other emerging viral infections. In this Viewpoint, we present our opinion on the benefits and potential limitations of using IFN-λ to prevent, limit, and treat these dangerous viral infections.
Document: With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-λ) realized that this class of IFNs could play an important role in this and other emerging viral infections. In this Viewpoint, we present our opinion on the benefits and potential limitations of using IFN-λ to prevent, limit, and treat these dangerous viral infections.
Search related documents:
Co phrase search for related documents- activation recruitment and lung inflammation: 1, 2, 3, 4, 5
- active disease and lung infection: 1, 2, 3, 4, 5, 6, 7
- active disease and lung inflammation: 1
Co phrase search for related documents, hyperlinks ordered by date